References
- Fonatsch C, Latza U, Durkop H, . Assignment of the human CD30 (Ki-1) gene to 1p36. Genomics 1992;14:825–826.
- Rezaei N, Haji-Molla-Hoseini M, Aghamohammadi A, . Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications. J Clin Immunol 2008;28:78–84.
- Casasnovas RO, Mounier N, Brice P, . Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:1732–1740.
- Zinzani PL, Pileri S, Bendandi M, . Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol 1998;16:1532–1537.
- Purdue MP, Lan Q, Martinez-Maza O, . A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730–2732.
- Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30: 631–637.
- Horie R, Ito K, Tatewaki M, . A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. Blood 1996;88:2422–2432.
- Essa EA, El Halim SM, Abo-Elenin A, . Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol 2007;14:11–20.
- Fathi AT, Preffer FI, Sadrzadeh H, . CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma 2013;54:860–863.
- Boissel N, Cayuela JM, Preudhomme C, . Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002;16:1699–1704.